The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Congrats on the collaboration. First, will you split up the responsibilities for polyneuropathy and cardiomyopathy any differently?
Or are they both 50-50 in the U.S., just given AstraZeneca's strength on the cardio side? And do you have any sense of what your
initial efforts in PN will look like? How many reps you'll need? And will those actually be your own reps? And then just remind us
what the time line is for the product outside the U.S.? And then I have one follow-up.
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Yes. No. And also, Brett, just the timelines outside the U.S.? With the filings, is it the same time? Or is that going to be a little bit later?
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Okay. And then just a couple of other follow-ups. Can we expect you to do something similar with losartan, just given the potential
of going into a much bigger market there with the severe high triglycerides, maybe having a partner for that opportunity? And then
with this deal with the additional funds and cost sharing, anything you would consider doing, you and AstraZeneca with
cardiomyopathy study to accelerate that timeline. Do you have anything in your control to be able to bring that forward a little bit
more?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: I was curious if you could zoom out and tell us a little bit just about the history of how this transaction came about as an inbound
interest from AZ. And also you just touched on this the prior question a little bit, but maybe even at a higher level, Brett, you've
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst
: Just a question on revenue guidance. I know you say above $600 million for the year. Is upfront payment on top of that? Or were
you making any adjustments to the revenue guidance? That's the first one.
And the second one is, is there any of the development milestones for today, would they be linked to the potential interim analysis
out of the CARDIO-TTRansform study or there's more milestones associated with that?
| 
